Source:http://linkedlifedata.com/resource/pubmed/id/15277008
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2004-7-27
|
| pubmed:abstractText |
The effect of therapeutic modalities on sexual potency is an important consideration for patients choosing a treatment for prostate cancer. We assessed erectile function after iridium-192 (1r-192) high-dose rate (HDR) brachytherapy with external beam radiation therapy (EBRT), and examined the efficacy of sildenafil after this treatment. Forty-two prostate cancer patients (T1c to T3bN0M0) were treated with 22Gy HDR brachytherapy with 36.8Gy EBRT without neoadjuvant hormone therapy. Erectile function was assessed using a 5-item version of the International Index of Erectile Function questionnaire (IIEF-5), pre, 3 and 12 months after treatment, Potency was defined as an IIEF-5 score > or = 11. Ten patients with potency before HDR brachytherapy with EBRT with or without neoadjuvant hormone therapy requested Sildenafil 3 months after treatment. The mean IIEF-5 score of all patients was 10.5 +/- 8.5, 4.5 +/- 5.3 (p < 0.001), and 3.8 +/- 4.7 (p < 0.001), pre, 3 and 12 months after treatment, respectively. Seventeen (40.4%) patients were potent before treatment. The mean IIEF-5 score of those patients was 15.8 +/- 3.2, 9.6 +/- 5.1 (p = 0.04), and 11.3 +/- 6.1 (p = 0.06), pre, 3 and 12 months after treatment, respectively. Ten of 17 (58.8%) patients maintained their potency 12 months after treatment. In 10 patients with potency before treatment who were treated with sildenafil, the mean IIEF-5 score increased from 6.2 +/- 3.5 at 3 months to 13.6 +/- 5.1 (p < 0.001) at 12 months after treatment. Eight of 10 (80%) patients treated with sildenafil had recovered 12 months after treatment. HDR brachytherapy with EBRT can be performed with favorable results for maintaining potency.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0148-5016
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
50
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
295-301
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:15277008-Adult,
pubmed-meshheading:15277008-Aged,
pubmed-meshheading:15277008-Brachytherapy,
pubmed-meshheading:15277008-Dose-Response Relationship, Radiation,
pubmed-meshheading:15277008-Erectile Dysfunction,
pubmed-meshheading:15277008-Follow-Up Studies,
pubmed-meshheading:15277008-Humans,
pubmed-meshheading:15277008-Iridium Radioisotopes,
pubmed-meshheading:15277008-Male,
pubmed-meshheading:15277008-Middle Aged,
pubmed-meshheading:15277008-Penile Erection,
pubmed-meshheading:15277008-Prostate-Specific Antigen,
pubmed-meshheading:15277008-Prostatic Neoplasms,
pubmed-meshheading:15277008-Questionnaires,
pubmed-meshheading:15277008-Time Factors
|
| pubmed:articleTitle |
Erectile function after brachytherapy with external beam radiation for prostate cancer.
|
| pubmed:affiliation |
Department of Urology Kawasaki Medical School, Kurashiki, Japan.
|
| pubmed:publicationType |
Journal Article
|